Insider Selling: Guardant Health, Inc. (NASDAQ:GH) Director Sells 538 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Ian T. Clark sold 538 shares of the firm’s stock in a transaction on Monday, December 28th. The shares were sold at an average price of $135.00, for a total transaction of $72,630.00. Following the completion of the transaction, the director now directly owns 5,181 shares of the company’s stock, valued at $699,435. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

GH stock opened at $128.88 on Friday. The business has a 50-day moving average price of $121.68 and a 200 day moving average price of $101.22. The company has a market capitalization of $12.88 billion, a P/E ratio of -67.48 and a beta of 0.58. Guardant Health, Inc. has a 1-year low of $55.90 and a 1-year high of $138.65.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.44). The firm had revenue of $74.66 million during the quarter, compared to the consensus estimate of $65.99 million. Guardant Health had a negative net margin of 67.14% and a negative return on equity of 19.22%. The business’s revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.14) earnings per share. On average, analysts predict that Guardant Health, Inc. will post -2.05 EPS for the current year.

Several research firms have commented on GH. ValuEngine lowered shares of Guardant Health from a “buy” rating to a “hold” rating in a research note on Tuesday, December 1st. SVB Leerink lifted their price objective on shares of Guardant Health from $130.00 to $150.00 and gave the stock an “outperform” rating in a research note on Friday, December 11th. BidaskClub lowered shares of Guardant Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, December 28th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Thursday, November 12th. Finally, Morgan Stanley lifted their price objective on shares of Guardant Health from $110.00 to $130.00 and gave the stock an “overweight” rating in a research note on Monday, November 9th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $133.00.

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in Guardant Health by 28.3% in the first quarter. FMR LLC now owns 464,612 shares of the company’s stock worth $35,636,000 after purchasing an additional 102,483 shares in the last quarter. First Trust Advisors LP raised its holdings in Guardant Health by 0.4% in the first quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock worth $5,513,000 after purchasing an additional 264 shares in the last quarter. Principal Financial Group Inc. raised its holdings in Guardant Health by 119.4% in the second quarter. Principal Financial Group Inc. now owns 31,337 shares of the company’s stock worth $2,542,000 after purchasing an additional 17,055 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Guardant Health by 140.1% in the second quarter. PNC Financial Services Group Inc. now owns 1,066 shares of the company’s stock worth $85,000 after purchasing an additional 622 shares in the last quarter. Finally, Macquarie Group Ltd. bought a new position in Guardant Health in the second quarter worth about $171,000. Hedge funds and other institutional investors own 76.15% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

See Also: Outstanding Shares, Buying and Selling Stocks

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.